The efficacy of a combination administration of gonadotropin-releasing hormone agonist and gonadotropins for controlled ovarian hyperstimulation in IVF program
- PMID: 2129188
- DOI: 10.1111/j.1447-0756.1990.tb00358.x
The efficacy of a combination administration of gonadotropin-releasing hormone agonist and gonadotropins for controlled ovarian hyperstimulation in IVF program
Abstract
In 105 patients with the past history of poor response to the previous controlled ovarian hyperstimulation (COH) due to poor follicular growth or premature LH surge, the efficacy of pituitary suppression with gonadotropin-releasing hormone agonist (GnRHa) in IVF/GIFT program was evaluated in 112 cycles of COH using a combination regimen of leuprolide acetate (Lupron) and FSH/hMG or pure FSH from May to December, 1989. After suppression phase, serum E2 and progesterone levels decreased significantly, but there was no change in serum LH and FSH levels. There was no occurrence of premature LH surge during COH. Eleven cycles (9.8%) were cancelled, and 3 cycles (3.0%) failed in the transvaginal oocytes retrieval. The 7.00 +/- 3.32 follicles (FD greater than or equal to 12 mm) were observed, and 6.11 +/- 4.15 oocytes were retrieved. The 3.59 +/- 2.57 oocytes were fertilized and cleaved with the cleavage rate of 55.7%. In 83 IVF patients, 4.08 +/- 2.39 embryos were transferred, and 16 pregnancies were obtained with the pregnancy rate per ET of 19.3%. In 6 GIFT patients, 7.83 +/- 3.31 oocytes were available for transfer. When compared with the previous 108 cycles, the cancellation rate during COH was decreased and all the parameters of the outcome of COH including the pregnancy rate were increased. These data suggest that GnRHa therapy for pituitary suppression is an effective adjunct to the current gonadotropin regimens for COH in IVF/GIFT and can increase the probability of oocytes retrieval and pregnancy, especially in the previous poor responders.
Similar articles
-
[A study of the controlled ovarian hyperstimulation using GnRH agonist and pure FSH in in vitro fertilization-embryo transfer and gamete intrafallopian transfer program].Nihon Sanka Fujinka Gakkai Zasshi. 1989 Sep;41(9):1431-8. Nihon Sanka Fujinka Gakkai Zasshi. 1989. PMID: 2511261 Japanese.
-
Determination of the efficiency of controlled ovarian hyperstimulation in the gonadotropin-releasing hormone agonist-suppression cycle using the initial follicle count during gonadotropin stimulation.J Assist Reprod Genet. 2001 Feb;18(2):91-6. doi: 10.1023/a:1026582608645. J Assist Reprod Genet. 2001. PMID: 11285987 Free PMC article.
-
Value of suppression with a gonadotropin-releasing hormone agonist prior to gonadotropin stimulation for in vitro fertilization.Fertil Steril. 1989 Feb;51(2):292-7. doi: 10.1016/s0015-0282(16)60493-4. Fertil Steril. 1989. PMID: 2492234 Clinical Trial.
-
Controlled ovarian hyperstimulation for the new reproductive technologies.Acta Eur Fertil. 1989 Jul-Aug;20(4):217-21. Acta Eur Fertil. 1989. PMID: 2519574 Review.
-
Use of gonadotropin-releasing hormone agonist to cause ovulation and prevent the ovarian hyperstimulation syndrome.Clin Obstet Gynecol. 1993 Sep;36(3):701-10. doi: 10.1097/00003081-199309000-00026. Clin Obstet Gynecol. 1993. PMID: 8403616 Review.
Cited by
-
Simultaneous program of natural-cycle in vitro fertilization and cryopreserved-thawed embryo transfer.J Assist Reprod Genet. 1996 Oct;13(9):716-21. doi: 10.1007/BF02066425. J Assist Reprod Genet. 1996. PMID: 8947820
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Miscellaneous